

Corporate News

August 10, 2016

MagForce AG announces positive results of 2016 Annual General Meeting

- The Annual General Meeting approves all agenda items with a clear majority
- Executive Board and Supervisory Board have been discharged

Berlin, Germany, August 10, 2016 – MagForce AG (Frankfurt, Entry Standard, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, held its Annual General Meeting in Berlin today. The Annual General Meeting approved all resolution items with a clear majority in excess of 98.8 percent.

The CEO and Chairman of the Management Board, Dr. Ben J. Lipps, reported the current operational developments and provided an overview of the 2015 fiscal year, as well as an outlook for the current year. Subsequently, he gave an update on the status of the strategic plan.

The Management Board presentation is available on the Company's website at www.magforce.de/en/presse-investoren/hauptversammlung.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm™ therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm[™], NanoPlan[®], and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm[™], NanoPlan, and NanoActivator® are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com

Get to know our Technology: video (You Tube)
Stay informed and subscribe to our mailing list

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes",

Page 1 of 2

 ${\sf MagForce}~{\sf AG} \bullet {\sf Max-Planck-Straße}~3 \bullet 12489~{\sf Berlin} \bullet {\sf Germany} \bullet {\sf www.magforce.com}$



"seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.